Stocks Comparison
Astrazeneca vs Johnson & Johnson: revenue, profit, margins and growth compared
Astrazeneca brought in $58.7B of revenue in fiscal 2025, Johnson & Johnson $94.2B in fiscal 2025. Revenue changed by +8.6% at Astrazeneca and +6.0% at Johnson & Johnson on the year before, so Astrazeneca grew faster. Astrazeneca kept 17.4% of its revenue as net profit, Johnson & Johnson 28.5%. Free cash flow was $11.8B at Astrazeneca and $19.7B at Johnson & Johnson.
Side by side, latest fiscal year
| AZN | JNJ | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 28, 2025) |
| Revenue | $58.7B | $94.2B |
| Revenue growth | +8.6% | +6.0% |
| Net income | $10.2B | $26.8B |
| Net margin | 17.4% | 28.5% |
| Free cash flow | $11.8B | $19.7B |
| Free cash flow margin | 20.0% | 20.9% |
| Earnings per share (diluted) | $6.54 | $11.03 |
| Cash | $5.7B | $19.7B |
| Debt | $29.6B | $41.4B |
| Price to earnings | n/a | 24.6 |
| Market value | $258.3B | $653.6B |
| Dividend yield | n/a | 1.90% |
| Rank by revenue in sector | #15 of 523 · Health care | #9 of 523 · Health care |
Over the years
Questions about Astrazeneca and Johnson & Johnson
Which is bigger by revenue, Astrazeneca or Johnson & Johnson?
Johnson & Johnson is bigger by revenue: $94.2B in fiscal 2025, against $58.7B for Astrazeneca in fiscal 2025.
Which keeps more of its revenue as profit, Astrazeneca or Johnson & Johnson?
Astrazeneca had a net margin of 17.4% in fiscal 2025; Johnson & Johnson had 28.5% in fiscal 2025.
Which grew revenue faster, Astrazeneca or Johnson & Johnson?
In their latest fiscal years revenue changed by +8.6% at Astrazeneca and +6.0% at Johnson & Johnson.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.